Community-led advocacy for transformational access to new HIV prevention tools in a changing world


Project Summary ———

Problem

Long acting injectable Lenacapavir (LEN-LA) has proven superior HIV prevention efficacy and can be produced for as little as \$40-100 per year, however the patent holder has a deeply restrictive pricing and access strategy. Structural and political barriers threaten to delay for years the introduction of affordable, generic LEN-LA at scale.

Proposed Solution

This collaboration between MSF and civil society partners aims to dramatically accelerate introduction and scale up of long acting anti-retrovirals (LA-ARV) for HIV prevention. The collective will: implement a community-led approach to advocacy for ARVs; secure enabling national policy environments regarding LEN-LA and other LA-ARVs in India, Brazil and South Africa; challenge and change the



most harmful aspects of patent holders' voluntary license and overall access strategy; and advocate for appropriate technical and financial resources to support LA-ARV introduction, procurement, and supply.

Area/Type: MRD; Incubator

Sponsor: MSF Southern Africa **Support:** OCB, MSF

Brazil, MSF USA, MSF UK, MSF India

Length/Project Status: 12 months; ONGOING



Potential Impact

 Aims to increase access to superior HIV prevention tools, particularly for criminalized and marginalized populations, resulting in reduced incidence of new HIV seroconversions in MSF programs and the local communities.

Viability

 Builds on partners' decades of experience successfully campaigning for access to medicines with affected populations.

Risk Mitigation

- Supports CSOs working on HIV prevention which are significantly at risk following the decimation of the international humanitarian funding system.
- Mitigates risks due to the current funding crisis by ongoing resource sharing and mobilisation amongst partners

Scalability

- Aims to reduce costs and increase funding associated with procuring HIV prevention intervention, enabling future scale-up.
- Develops tools and knowledge to facilitate advocacy work within and beyond MSF, for access to LA-ARVs and eventually other products.